# LLY Intraday Execution Update

- Analysis As-Of: `2026-04-15T02:06:59.866670+09:00`
- Market Data As-Of: `2026-04-14T15:25:00-04:00`
- Execution As-Of: `2026-04-15T04:28:13.550419+09:00`
- Decision State: **DEGRADED**
- Decision Now: **NONE**
- Decision If Triggered: **NONE**
- Staleness: `193s`
- Data Health: `STALE`

## Explanation

- `LLY` stays `BULLISH` with a `watch_only` setup: `entry_action_base` is `WAIT`, `setup_quality` is `DEVELOPING`, and `confidence` is `0.66`; the key triggers remain a close above `955` with RSI > `50` and volume expansion, then strength through the `981-985` 50-day SMA zone, while `900-901` remains the retest support area.
- The execution update is now `NO_TRADE` / `NONE` because the intraday tape weakened: `last_price` is `924.6599731445312`, below `session_vwap` `930.7266077115664`, with `relative_volume` `0.5784059400966356`, `price_state` `INTRADAY`, `volume_state` `UNCONFIRMED`, `event_state` `OPEN`, `decision_state` `DEGRADED`, and `data_health` `STALE` with `staleness_seconds` `193` and `refresh_checkpoint` `03:35`.
- The constructive thesis is still supported by `Foundayo` approval and `$149/month` U.S. launch potential, 2025 quarterly revenue rising from `12.7b` to `15.6b` to `17.6b` to `19.3b` `usd`, about `9.0B` 4Q operating profit and about `45%` margin, plus `Centessa` and `CrossBridge Bio` acquisitions and `Jaypirca` `3상` positive data.